Exelixis (EXEL) –
-
Form ARS EXELIXIS, INC. For: Dec 31
-
Form DEFA14A EXELIXIS, INC.
-
Form DEF 14A EXELIXIS, INC. For: May 30
-
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
-
Barclays Downgrades Exelixis (EXEL) to Equalweight
-
Form 8-K EXELIXIS, INC. For: Mar 27
-
Form 4 EXELIXIS, INC. For: Mar 21 Filed by: Garber Alan M
-
Form 144 EXELIXIS, INC. Filed by: Garber Alan M
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Peterson Amy C.
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: MORRISSEY MICHAEL
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Aftab Dana
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Hessekiel Jeffrey
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Senner Christopher J.
-
Form 4 EXELIXIS, INC. For: Feb 23 Filed by: Haley Patrick J.
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
-
Form 144 EXELIXIS, INC. Filed by: Haley Patrick J.
-
Form 4 EXELIXIS, INC. For: Feb 21 Filed by: Caligan Partners LP
-
Form 4 EXELIXIS, INC. For: Feb 15 Filed by: Aftab Dana
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Form SC 13G/A EXELIXIS, INC. Filed by: VANGUARD GROUP INC
-
Form SC 13G EXELIXIS, INC. Filed by: RENAISSANCE TECHNOLOGIES LLC
-
Exelixis (EXEL) PT Raised to $28 at RBC Capital
-
Form 10-K EXELIXIS, INC. For: Dec 29
-
Form 8-K EXELIXIS, INC. For: Feb 06
-
Exelixis (EXEL) Tops Q4 EPS by 10c, offers guidance
-
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
-
Exelixis (EXEL) PT Raised to $25 at Stifel
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
-
Exelixis (EXEL) PT Raised to $25 at Barclays
-
Exelixis (EXEL) Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial of Cabozantinib in Combination with Atezolizumab
-
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU
-
Form SC 13G/A EXELIXIS, INC. Filed by: BlackRock Inc.
-
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
-
Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell
-
Exelixis (EXEL) Reports EU Patent Office Ruled in Favor of Exelixis on Formulation Patent Covering CABOMETYX
-
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
-
Exelixis (EXEL) PT Raised to $28 at Wells Fargo
-
Form 4 EXELIXIS, INC. For: Jan 11 Filed by: MORRISSEY MICHAEL
-
Form 4 EXELIXIS, INC. For: Jan 11 Filed by: Senner Christopher J.
-
Form 4 EXELIXIS, INC. For: Jan 11 Filed by: Haley Patrick J.
-
Form 4 EXELIXIS, INC. For: Jan 11 Filed by: Hessekiel Jeffrey
-
Form 4 EXELIXIS, INC. For: Jan 05 Filed by: Eckhardt Sue Gail
-
Form 4 EXELIXIS, INC. For: Jan 05 Filed by: Beckerle Mary C
-
Form 3 EXELIXIS, INC. For: Jan 05 Filed by: Eckhardt Sue Gail
-
Form 3 EXELIXIS, INC. For: Jan 05 Filed by: Beckerle Mary C
-
Form 8-K EXELIXIS, INC. For: Jan 02
-
Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance
-
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
-
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Back to EXEL Stock Lookup
